Gracell Biotechnologies Inc., a China-based global clinical-stage biopharmaceutical company, announced on Tuesday that it has named Samuel Zhang, PhD as its new chief business officer (CBO).

In the new role, Dr Zhang will handle strategic leadership of the company's global business development and corporate strategy, including structuring, negotiating and implementation of strategic alliances and collaborations.

Zhang has held the position of CBO at NeoImmuneTech. He has also served in positions of increasing responsibility at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.